AlphAIalphai — Financial news for AI agents
stocktwits.comSEP 42 min read$NVS

NVS, IONS, AMGN Stocks Drop After-Hours — What’s Driving The Selloff?

Novartis (NVS) and Ionis (IONS) shares dropped after-hours Friday after a heart-disease trial for pelacarsen failed to show reduced risk of heart attacks or strokes, despite lowering lipoprotein(a). NVS fell 7%, IONS 10%. Amgen (AMGN) also dropped 5% as it develops a similar drug. NVS closed at $159.99. Both NVS and IONS have seen significant YTD changes, up 16% and down 27% respectively.

Original reporting
stocktwits.com
Published Sep 4, 2026, 3:57 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 5, 2026, 12:03 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefTechnology
Primary signal
$NVS
Bearish
high confidence
Mentioned
$NVS · $IONS · $AMGN
Relevance
8/10
alphai data visualization · based on stocktwits.com
Decision brief

The 30-second read

$NVSBearishHigh
01

Why it matters

The trial failure is expected to depress near‑term valuations for the three companies involved and may slow investor enthusiasm for Lp(a)‑targeting therapies.

02

Market read

First‑hand trial data causing multi‑stock sell‑off in the cardiovascular biotech niche.

03

What to watch

Novartis’s other late‑stage programs (remibrutinib, ianalumab) could offset the setback.

Relevance 8/10Novelty 8/10Timing: after-hours Friday

Background

The article reports the first public disclosure of the Lp(a)HORIZON trial results for pelacarsen, a key asset for Novartis and Ionis.

Company-level read

Ticker impact

$NVSBearishHigh confidence
Context

Novartis shares fell ~7% after-hours as its Lp(a) trial failed to show cardiovascular benefit.

Expected impact

Further downside pressure in the short term.

Evidence & confidence

First disclosure of a failed late‑stage trial for a major pipeline asset.

$IONSBearishHigh confidence
Context

Ionis stock dropped ~10% after-hours as its partner Novartis reported the pelacarsen trial miss.

Expected impact

Continued sell‑off until pipeline updates.

Evidence & confidence

Direct financial impact from partner’s missed outcome.

$AMGNBearishMedium confidence
Context

Amgen shares slipped 5% after hours as its competing Lp(a) program faced a similar trial disappointment.

Expected impact

Potential short‑term weakness pending further data.

Evidence & confidence

Market reaction to sector‑wide setback, though not a direct trial result for Amgen.

Market effects

Sector

Lipoprotein(a) therapeutic space faces heightened scrutiny, affecting biotech peers.

Regional

European and US biotech indices may see modest pullback.

Global

Limited to cardiovascular‑focused biotech sector.

Counterpoint

What could challenge this read

Investors may view the miss as a buying opportunity if the broader pipeline remains strong.

Key entities

  • company
    Novartis

    Swiss pharma giant with US‑listed ADR NVS.

  • company
    Ionis Pharmaceuticals

    US biotech partner IONS.

  • company
    Amgen

    US biotech AMGN developing a competing Lp(a) drug.

Read at source← All news

Related articles

SEP 4
$AMGNMed

Amgen Slides as Tavneos Regulatory Pressure Weighs on Sentiment

Amgen (AMGN) shares fell 6.8% after U.K. regulators suspended Tavneos for new patients, citing concerns about its efficacy. The FDA also proposed withdrawing the drug in the U.S., raising regulatory risks. Tavneos contributes a small portion of Amgen's revenue. Insider sales, hedge fund activity, and analyst price targets were also noted.

quiverquant.com2 min
SEP 4
$NVSMedAI 8/10

Novartis Pharma AG: Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)

Novartis announced that the Phase III Lp(a)HORIZON trial for pelacarsen did not meet its primary endpoint of reducing cardiovascular events. The study, involving 8,323 patients, showed that while pelacarsen lowered Lp(a) levels, it did not reduce cardiovascular risk. Novartis obtained rights to pelacarsen from Ionis Pharmaceuticals. Elevated Lp(a) affects about 20% of people worldwide and has no approved targeted treatment.

finanznachrichten.de2 min
SEP 4
$AMGNMedAI 8/10

Amgen (AMGN) Says Repatha Reduced Mortality Before a First Heart Attack or Stroke. Can Earlier Use Expand the Market?

Amgen (AMGN) reported Repatha reduced all-cause mortality by 20% in a secondary analysis of the VESALIUS-CV trial. The study involved over 12,000 high-risk adults without prior heart attacks or strokes. Repatha also lowered cardiovascular risks and LDL-C levels. Amgen aims to expand use before first major cardiovascular events, citing 15 years of clinical trials and global use in 9 million patients.

yahoo.com2 min
SEP 4
$IONSHighAI 9/10

Weekly Buzz: IONS, MIST, BIIB, AZN Win Nods; TCRX, NVS Cut Jobs; OVID, VIR Data; REGN, PASG Deals

Ionis (IONS) and Milestone (MIST) gained FDA approvals for neurology and cardiology drugs. Biogen (BIIB) and AstraZeneca (AZN) also received regulatory nods for Alzheimer's and cancer treatments. Novavax (NVAX) secured global approvals for its COVID-19 vaccine. TScan (TCRX) and Novartis (NVS) announced job cuts. Novartis (NVS) and HUTCHMED (HCM) struck deals worth up to $3.2B and $1.295B respectively.

rttnews.com3 min
SEP 4
$IONSHighAI 9/10

IONS Secures FDA Nod for Rare Brain Disorder Drug Zanvastro

Ionis Pharmaceuticals (IONS) received FDA approval for Zanvastro, a treatment for Alexander disease, ahead of the expected date. The drug, backed by positive phase III study results, is the first disease-modifying treatment for this rare neurological condition. Ionis shares have fallen 27% year-to-date, and the company also received a rare pediatric disease priority review voucher, which could provide additional value.

yahoo.com3 min
NVS, IONS, AMGN Stocks Drop After-Hours — What’s Driving The Selloff? — alphai